Sistema de Salut de Catalunya
Institut Català de la Salut
[Ciudin A] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Fisiologia Humana i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDem), Instituto de Salud Carlos III, Madrid, Spain. [Simó R] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDem), Instituto de Salud Carlos III, Madrid, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-01-09T12:29:13Z
2023-01-09T12:29:13Z
2022-12-01
Dementia; Retinal microperimetry; Type 2 diabetes
Demencia; Microperimetría retiniana; Diabetes tipo 2
Demència; Microperimetria retiniana; Diabetis tipus 2
The presence of type 2 diabetes acts as an accelerator of cognitive impairment (mild cognitive impairment and later dementia), with a significant impact on the management of the disease and its complications. Therefore, it is recommended to perform an annual evaluation of cognitive function in patients with diabetes older than 65 years. Current guidelines still recommend the use of the Minimental State Evaluation Test (MMSE) as screening test, but it has a modest sensitivity and specificity for identifying mild cognitive impairment. This represents an important gap because patients with mild cognitive impairment are at risk of progressing to dementia. The neurocognitive diagnosis is based on complex neuropsychological tests, which require specifically trained personnel and are time consuming, making its routine incorporation into daily clinical practice unfeasible. Therefore, at present there are no reliable biomarkers to identify patients with type 2 diabetes at increased risk of developing cognitive impairment. Since the brain and the retina have a common embryological origin, our Research Group, has worked over the last 10 years evaluating the usefulness of the retina as a “window” to the brain. We provided evidence that retinal microperimetry is a simple, feasible and useful tool for screening and monitoring cognitive function in patients with type 2 diabetes. We propose a review of actual tests recommended for screening of cognitive impairment as well as an update of new emerging methods, such as retinal microperimetry.
Article
Published version
English
Diabetis no-insulinodependent - Complicacions; Trastorns de la cognició - Diagnòstic; Tests neuropsicològics; DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2; Other subheadings::Other subheadings::Other subheadings::/complications; PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurocognitive Disorders::Cognition Disorders::Cognitive Dysfunction; Other subheadings::Other subheadings::/diagnosis; PSYCHIATRY AND PSYCHOLOGY::Behavioral Disciplines and Activities::Psychological Tests::Neuropsychological Tests; ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II; Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones; PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos neurocognitivos::trastornos cognitivos::disfunción cognitiva; Otros calificadores::Otros calificadores::/diagnóstico; PSIQUIATRÍA Y PSICOLOGÍA::disciplinas y actividades conductuales::pruebas psicológicas::pruebas neuropsicológicas
Frontiers Media
Frontiers in Endocrinology;13
https://doi.org/10.3389/fendo.2022.1024794
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1665]
